Aspirin not associated with decreased prostate cancer-associated mortality
the ONA take:
According to a recent study published in The Journal of Urology, researchers from Jewish General Hospital in Montreal, Quebec, Canada, have found that aspirin use does not decrease the risk of mortality associated with prostate cancer.
For the study, researchers followed a cohort of 11,779 men diagnosed with nonmetastatic prostate cancer between 1998 and 2009. Patients were followed until 2012 in order to assess associations between aspirin use and both prostate and all-cause mortality.
Results showed that a median follow-up of 5.4 years, aspirin use after cancer diagnosis was associated with increased risks of prostate cancer mortality (HR = 1.46; 95% CI: 1.26-1.50).
Researchers also found that the risk of prostate cancer-associated mortality was increased in patients who started using aspirin after they were were diagnosed with cancer (HR = 1.84; 95% CI: 1.59-2.12), whereas those who were using aspirin before diagnosis did not have an increased risk of cancer-associated mortality (HR = 0.97; 95% CI: 0.81-1.16.
The study showed similar risks for all cause-mortality and post- and pre-diagnostic aspirin use.
Aspirin use does not decrease the risk of mortality associated with prostate cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|